EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--SurModics, Inc. (Nasdaq: SRDX - News), a leading provider of surface modification and drug delivery technologies to the healthcare industry, today announced that the SynBiosys™ biodegradable drug delivery polymer system was incorporated in a first in-human trial evaluating a new small vessel stent. The stent, developed by CardioMind, Inc., of Sunnyvale, CA, allows cardiologists to treat blood vessels with diameters smaller than 2.75 mm. The implant procedures were performed at St. Vincent’s Hospital in Melbourne, Australia, as part of CardioMind’s CARE II clinical trial.
